Mohammed Azeemuddin, Suryakanth D Anturlikar, Mallappa Onkaramurthy, Mirza R Baig, Basti K Ashok, Raghavendra P Rao, Mohamed Rafiq, Paramesh Rangesh
{"title":"复方DXB-2030对实验性多囊卵巢综合征伴高雄激素血症的影响","authors":"Mohammed Azeemuddin, Suryakanth D Anturlikar, Mallappa Onkaramurthy, Mirza R Baig, Basti K Ashok, Raghavendra P Rao, Mohamed Rafiq, Paramesh Rangesh","doi":"10.1155/2019/8272850","DOIUrl":null,"url":null,"abstract":"<p><p>The objective of the present study was to evaluate \"DXB-2030,\" a polyherbal combination of <i>Trigonella foenum-graecum</i>, <i>Aloe vera</i>, <i>Sphaeranthus indicus</i>, <i>Nardostachys jatamansi</i>, and <i>Symplocos racemosa</i> extracts in an experimental model of testosterone propionate (TP), induced polycystic ovary syndrome (PCOS) in female rats. Thirty animals were divided into 3 groups of 10 each; group 1 served as normal control; group 2 was administered with TP and served as positive control; along with TP, group 3 was treated with \"DXB-2030\" at a dose of 100 mg/kg p.o., for 60 days. At the end of the study period, the animals were subjected for the estimation of serum testosterone levels, oral glucose tolerance test (OGTT), weight of the ovaries, estrous cycle, and histopathological evaluation. An in vitro assay on GLUT4 expression was carried out to understand the effect of \"DXB-2030\" on insulin resistance. Results showed that treatment with \"DXB-2030\" reversed the TP-induced changes by increasing the GLUT4 expression and decreasing the body weight, testosterone levels, AUC of glucose in OGTT, and the cystic follicles of the ovaries, thus indicating its beneficial effect in PCOS by ameliorating the metabolic dysfunction and reproductive impairment, which are the pathophysiological conditions associated with PCOS. From the results obtained, it can be concluded that \"DXB-2030\" was effective in the management of experimental PCOS and hence may be recommended in the treatment of PCOS.</p>","PeriodicalId":7389,"journal":{"name":"Advances in Pharmacological Sciences","volume":"2019 ","pages":"8272850"},"PeriodicalIF":0.0000,"publicationDate":"2019-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/8272850","citationCount":"8","resultStr":"{\"title\":\"Effect of \\\"DXB-2030,\\\" a Polyherbal Formulation, on Experimental Polycystic Ovary Syndrome Associated with Hyperandrogenism.\",\"authors\":\"Mohammed Azeemuddin, Suryakanth D Anturlikar, Mallappa Onkaramurthy, Mirza R Baig, Basti K Ashok, Raghavendra P Rao, Mohamed Rafiq, Paramesh Rangesh\",\"doi\":\"10.1155/2019/8272850\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The objective of the present study was to evaluate \\\"DXB-2030,\\\" a polyherbal combination of <i>Trigonella foenum-graecum</i>, <i>Aloe vera</i>, <i>Sphaeranthus indicus</i>, <i>Nardostachys jatamansi</i>, and <i>Symplocos racemosa</i> extracts in an experimental model of testosterone propionate (TP), induced polycystic ovary syndrome (PCOS) in female rats. Thirty animals were divided into 3 groups of 10 each; group 1 served as normal control; group 2 was administered with TP and served as positive control; along with TP, group 3 was treated with \\\"DXB-2030\\\" at a dose of 100 mg/kg p.o., for 60 days. At the end of the study period, the animals were subjected for the estimation of serum testosterone levels, oral glucose tolerance test (OGTT), weight of the ovaries, estrous cycle, and histopathological evaluation. An in vitro assay on GLUT4 expression was carried out to understand the effect of \\\"DXB-2030\\\" on insulin resistance. Results showed that treatment with \\\"DXB-2030\\\" reversed the TP-induced changes by increasing the GLUT4 expression and decreasing the body weight, testosterone levels, AUC of glucose in OGTT, and the cystic follicles of the ovaries, thus indicating its beneficial effect in PCOS by ameliorating the metabolic dysfunction and reproductive impairment, which are the pathophysiological conditions associated with PCOS. From the results obtained, it can be concluded that \\\"DXB-2030\\\" was effective in the management of experimental PCOS and hence may be recommended in the treatment of PCOS.</p>\",\"PeriodicalId\":7389,\"journal\":{\"name\":\"Advances in Pharmacological Sciences\",\"volume\":\"2019 \",\"pages\":\"8272850\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-02-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2019/8272850\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Pharmacological Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2019/8272850\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2019/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Pharmacological Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2019/8272850","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Effect of "DXB-2030," a Polyherbal Formulation, on Experimental Polycystic Ovary Syndrome Associated with Hyperandrogenism.
The objective of the present study was to evaluate "DXB-2030," a polyherbal combination of Trigonella foenum-graecum, Aloe vera, Sphaeranthus indicus, Nardostachys jatamansi, and Symplocos racemosa extracts in an experimental model of testosterone propionate (TP), induced polycystic ovary syndrome (PCOS) in female rats. Thirty animals were divided into 3 groups of 10 each; group 1 served as normal control; group 2 was administered with TP and served as positive control; along with TP, group 3 was treated with "DXB-2030" at a dose of 100 mg/kg p.o., for 60 days. At the end of the study period, the animals were subjected for the estimation of serum testosterone levels, oral glucose tolerance test (OGTT), weight of the ovaries, estrous cycle, and histopathological evaluation. An in vitro assay on GLUT4 expression was carried out to understand the effect of "DXB-2030" on insulin resistance. Results showed that treatment with "DXB-2030" reversed the TP-induced changes by increasing the GLUT4 expression and decreasing the body weight, testosterone levels, AUC of glucose in OGTT, and the cystic follicles of the ovaries, thus indicating its beneficial effect in PCOS by ameliorating the metabolic dysfunction and reproductive impairment, which are the pathophysiological conditions associated with PCOS. From the results obtained, it can be concluded that "DXB-2030" was effective in the management of experimental PCOS and hence may be recommended in the treatment of PCOS.
期刊介绍:
Advances in Pharmacological and Pharmaceutical Sciences is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies in all areas of experimental and clinical pharmacology, pharmaceutics, medicinal chemistry and drug delivery. Topics covered by the journal include, but are not limited to: -Biochemical pharmacology, drug mechanism of action, pharmacodynamics, pharmacogenetics, pharmacokinetics, and toxicology. -The design and preparation of new drugs, and their safety and efficacy in humans, including descriptions of drug dosage forms. -All areas of medicinal chemistry, such as drug discovery, design and synthesis. -Basic biology of drug and gene delivery through to application and development of these principles, through therapeutic delivery and targeting. Areas covered include bioavailability, controlled release, microcapsules, novel drug delivery systems, personalized drug delivery, and techniques for passing biological barriers.